Halyard Health, Inc. (NYSE:HYH) has earned an average rating of “Buy” from the seven research firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $42.25.

A number of equities analysts have recently commented on HYH shares. TheStreet raised shares of Halyard Health from a “c” rating to a “b” rating in a research report on Thursday, June 22nd. BidaskClub raised shares of Halyard Health from a “hold” rating to a “buy” rating in a research report on Saturday, August 19th. Deutsche Bank AG lifted their price target on shares of Halyard Health from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, August 3rd. Zacks Investment Research raised shares of Halyard Health from a “hold” rating to a “buy” rating and set a $44.00 price target on the stock in a research report on Wednesday, July 12th. Finally, Stephens raised shares of Halyard Health from an “equal weight” rating to an “overweight” rating in a research report on Thursday, August 3rd.

ILLEGAL ACTIVITY WARNING: “Halyard Health, Inc. (HYH) Receives $42.25 Average Price Target from Brokerages” was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://theolympiareport.com/2017/09/11/halyard-health-inc-hyh-receives-42-25-average-price-target-from-brokerages.html.

Several institutional investors have recently made changes to their positions in the company. Koch Industries Inc. acquired a new stake in shares of Halyard Health in the second quarter worth $297,000. Sterling Capital Management LLC acquired a new stake in shares of Halyard Health in the second quarter worth $631,000. Raymond James Financial Services Advisors Inc. acquired a new stake in shares of Halyard Health in the second quarter worth $217,000. The Manufacturers Life Insurance Company grew its stake in shares of Halyard Health by 0.6% in the second quarter. The Manufacturers Life Insurance Company now owns 102,917 shares of the medical instruments supplier’s stock worth $4,042,000 after acquiring an additional 575 shares during the last quarter. Finally, State Street Corp grew its stake in shares of Halyard Health by 7.5% in the second quarter. State Street Corp now owns 1,702,423 shares of the medical instruments supplier’s stock worth $66,872,000 after acquiring an additional 119,154 shares during the last quarter. Institutional investors and hedge funds own 91.02% of the company’s stock.

Shares of Halyard Health (HYH) traded up 0.15% on Wednesday, hitting $45.90. 332,294 shares of the stock traded hands. Halyard Health has a 12-month low of $31.59 and a 12-month high of $46.36. The stock has a 50-day moving average price of $42.66 and a 200 day moving average price of $39.42. The stock has a market cap of $2.14 billion, a price-to-earnings ratio of 44.13 and a beta of 1.76.

Halyard Health (NYSE:HYH) last released its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.51 EPS for the quarter, beating the Zacks’ consensus estimate of $0.37 by $0.14. Halyard Health had a net margin of 3.06% and a return on equity of 8.29%. The company had revenue of $399.20 million for the quarter, compared to analyst estimates of $399.16 million. During the same quarter last year, the firm posted $0.45 earnings per share. The company’s quarterly revenue was down .2% compared to the same quarter last year. On average, analysts anticipate that Halyard Health will post $1.98 earnings per share for the current fiscal year.

About Halyard Health

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.